Circulating cell-free DNA is a potential prognostic biomarker of metastatic castration-resistant prostate cancer for taxane therapy

Prostate cancer (PC) is the most frequently diagnosed cancer and a major cause of cancer deaths among men in the developed countries (1). Metastatic prostate cancer remains the major challenge in PC treatment. Despite standard treatment with androgen deprivation therapy (ADT), patients with metastatic PC will inevitably progress to metastatic castration-resistant prostate cancer (mCRPC).